Publication: High throughput assay for the determination of piperaquine in plasma
1
Issued Date
2005-09-15
Resource Type
ISSN
07317085
Other identifier(s)
2-s2.0-23944465725
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Pharmaceutical and Biomedical Analysis. Vol.39, No.3-4 (2005), 601-605
Suggested Citation
N. Lindegårdh, N. J. White, N. P J Day High throughput assay for the determination of piperaquine in plasma. Journal of Pharmaceutical and Biomedical Analysis. Vol.39, No.3-4 (2005), 601-605. doi:10.1016/j.jpba.2005.03.031 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/16431
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
High throughput assay for the determination of piperaquine in plasma
Author(s)
Other Contributor(s)
Abstract
A high throughput assay for the determination of the antimalarial piperaquine in plasma has been developed and validated. The assay utilises 96-wellplate formats throughout the whole procedure, and easily enables a throughput of 192 samples a day using a single LC system. Buffer (pH 2.0; 0.05 M) containing internal standard was added to 0.25 mL plasma in a 96-wellplate (2 mL wells). The samples were extracted on a MPC solid phase extraction deep well 96-wellplate (3 M Empore). Piperaquine and internal standard were analysed by liquid chromatography with UV detection on a Chromolith Performance (100 mm × 4.6 mm) column with a mobile phase containing acetonitrile-phosphate buffer (pH 2.5; 0.1 M) (8:92, v/v) at a flow rate of 3.0 mL/min. The within-day precisions for piperaquine were 3.3 and 2.3% at 40 and 1250 ng/mL, respectively. The between-day precisions for piperaquine were 5.8 and 1.3% at 40 and 1250 ng/mL, respectively. The total assay precisions using 29 replicates over 5 days were 6.7, 4.5 and 2.7% at 40, 200 and 1250 ng/mL, respectively. The lower limit of quantification (LLOQ) and the limit of detection (LOD) were 10 and 5 ng/mL, respectively using 0.25 mL plasma. Using 1 mL of plasma, it was possible to decrease LLOQ and LOD to 2.5 and 1.25 ng/mL, respectively. © 2005 Elsevier B.V. All rights reserved.